Molecular and cellular biology of prostate cancer

Prostate cancer is an enigmatic disease. Although prostatic-intraepithelial neoplasia appears as early as the third decade and as many as 80% of 80 year old men have epithelial cells in their prostate that fit the morphological criteria for cancer, only about 10% of men will ever have the clinical disease and less than 3% will die from it. There have been no significant proven interventions which have altered the natural history of the disease since hormone down regulation was introduced in the 1940s and new research has been poorly supported. There is however an urgent need to develop new criteria to distinguish those patients with localised disease who will benefit from intervention from those that do not require it or who will have occult extra prostatic metastases. Similarly, there is an urgent need to develop new treatment for those in whom the disease is extra-prostatic and therefore incurable by conventional treatments. This review covers the latest developments in epidemiology, cellular and molecular biology including new areas such as ion channels in the field of prostate cancer.

[1]  D. Peehl Oncogenes in prostate cancer. An update , 1993, Cancer.

[2]  J. Pancrazio,et al.  Voltage-activated K+ conductance and cell proliferation in small-cell lung cancer. , 1993, Anticancer research.

[3]  S. Dedhar,et al.  Identification of a novel form of the alpha 3 integrin subunit: covalent association with transferrin receptor. , 1995, The Biochemical journal.

[4]  C. Turc‐Carel,et al.  Chromosomes in solid tumors and beyond. , 1988, Cancer research.

[5]  P. Reinach,et al.  Effects of androgen on intracellular calcium of LNCaP cells. , 1991, Biochemical and biophysical research communications.

[6]  K. Pienta,et al.  Effect of pentosan, a novel cancer chemotherapeutic agent, on prostate cancer cell growth and motility , 1992, The Prostate.

[7]  D. Neal,et al.  Peptide growth factors in the prostate as mediators of stromal epithelial interaction. , 1996, British journal of urology.

[8]  A. Schuurmans,et al.  Androgens stimulate both growth rate and epidermal growth factor receptor activity of the human prostate tumor cell LNCaP , 1988, The Prostate.

[9]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[10]  J. Barnard,et al.  Androgen up-regulates epidermal growth factor receptor expression and binding affinity in PC3 cell lines expressing the human androgen receptor. , 1995, Cancer research.

[11]  Lars Holmgren,et al.  Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression , 1995, Nature Medicine.

[12]  P. Abel,et al.  Expression and functional analysis of voltage-activated Na+ channels in human prostate cancer cell lines and their contribution to invasion in vitro. , 1997, The American journal of pathology.

[13]  D. Isenberg,et al.  Serum metalloproteinases and their inhibitors: markers for malignant potential. , 1994, British Journal of Cancer.

[14]  R. Miesfeld,et al.  Functional characterizations of the androgen receptor confirm that the molecular basis of androgen action is transcriptional regulation. , 1990, Molecular endocrinology.

[15]  C. Chang,et al.  Nuclear localization of androgen receptor in heterogeneous samples of normal, hyperplastic and neoplastic human prostate. , 1992, The Journal of urology.

[16]  W. Lee,et al.  Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[17]  R. Franklin,et al.  Effect of prolactin on the prostate , 1994, The Prostate.

[18]  L. Chung,et al.  Hormone-induced morphogenesis and growth: role of mesenchymal-epithelial interactions. , 1983, Recent progress in hormone research.

[19]  S. Magnuson,et al.  Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. , 1996, Cancer research.

[20]  S. Dedhar,et al.  Specific alterations in the expression of α3β1 and α6β4 integrins in highly invasive and metastatic variants of human prostate carcinoma cells selected by in vitro invasion through reconstituted basement membrane , 1993, Clinical & Experimental Metastasis.

[21]  R. Cohen,et al.  The neuroendocrine cell population of the human prostate gland. , 1993, The Journal of urology.

[22]  E. Hedley‐Whyte,et al.  Prognostic role of urokinase-type plasminogen activator in human gliomas. , 1995, The American journal of pathology.

[23]  A. Belldegrun,et al.  In vitro modulation of tumor progression‐associated properties of hormone refractory prostate carcinoma cell lines by cytokines , 1996, Cancer.

[24]  D. Paulson,et al.  Spontaneous metastasis of cells of the human prostate carcinoma cell line PC-3 in athymic nude mice. , 1982, The Journal of urology.

[25]  H. Klocker,et al.  Androgen signal transduction and prostatic carcinoma , 2004, World Journal of Urology.

[26]  M. Susin,et al.  Mutational status of codons 12 and 13 of the N- and K-ras genes in tissue and cell lines derived from primary and metastatic prostate carcinomas. , 1993, Cancer investigation.

[27]  D. Hanahan,et al.  Switch to the angiogenic phenotype during tumorigenesis. , 1991, Princess Takamatsu symposia.

[28]  J. Lechner,et al.  Establishment and characterization of a human prostatic carcinoma cell line (PC-3). , 1979, Investigative urology.

[29]  J. Folkman Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[30]  E. Wanke,et al.  Response to fibronectin–integrin interaction in leukaemia cells: delayed enhancing of a K+ current , 1992, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[31]  C. Higgins Volume‐activated chloride currents associated with the multidrug resistance P‐glycoprotein. , 1995, The Journal of physiology.

[32]  Chawnshang Chang,et al.  Immunohistochemical study of androgen receptor in benign hyperplastic and cancerous human prostates , 1990, The Prostate.

[33]  W. Wonderlin,et al.  Changes in membrane potential during the progression of MCF‐7 human mammary tumor cells through the cell cycle , 1995, Journal of cellular physiology.

[34]  C. Polychronakos,et al.  Proteinolytic activity against IGF-binding proteins involved in the paracrine interactions between prostate adenocarcinoma cells and osteoblasts. , 1992, Anticancer research.

[35]  R. Sadasivan,et al.  Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate cancer. , 1993, The Journal of urology.

[36]  J. Schalken,et al.  Down modulation of fibronectin messenger RNA in metastasizing rat prostatic cancer cells revealed by differential hybridization analysis. , 1988, Cancer research.

[37]  W. Wonderlin,et al.  Inhibition of ATP‐sensitive potassium channels causes reversible cell‐cycle arrest of human breast cancer cells in tissue culture , 1995, Journal of cellular physiology.

[38]  B. Allolio,et al.  Antiproliferative and angiostatic activity of suramin analogues. , 1995, Cancer research.

[39]  B. Tribukait Flow cytometry in assessing the clinical aggressiveness of genito-urinary neoplasms , 1987, World Journal of Urology.

[40]  W. Haenszel,et al.  Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. , 1968, Journal of the National Cancer Institute.

[41]  D. Pa Neuroendocrine differentiation in the precursors of prostate cancer , 1996 .

[42]  U. Bergerheim,et al.  Deletion mapping of chromosomes 8, 10, and 16 in human prostatic carcinoma , 1991, Genes, chromosomes & cancer.

[43]  T. Nakajima,et al.  Nitric oxide-mediated apoptosis in murine mastocytoma. , 1994, Biochemical and biophysical research communications.

[44]  K. Cooney,et al.  Distinct regions of allelic loss on 13q in prostate cancer. , 1996, Cancer research.

[45]  J. Southgate,et al.  Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ , 1989, Cell.

[46]  D. Rose,et al.  Production of epidermal growth factor and transforming growth factor‐α by the androgen‐responsive LNCaP human prostate cancer cell line , 1990, The Prostate.

[47]  S. J. Higgins,et al.  The endocrinology and developmental biology of the prostate. , 1987, Endocrine reviews.

[48]  R. Kiss,et al.  Influence of dihydrotestosterone, epidermal growth factor, and basic fibroblast growth factor on the cell kinetics of the PC3, DUI45, and LNCap prostatic cancer cell lines: Relationship with DNA ploidy level , 1995, The Prostate.

[49]  L M Loew,et al.  Electric field-directed fibroblast locomotion involves cell surface molecular reorganization and is calcium independent , 1994, The Journal of cell biology.

[50]  W Blumenfeld,et al.  Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. , 1993, The American journal of pathology.

[51]  J. McNeal,et al.  Origin and development of carcinoma in the prostate , 1969, Cancer.

[52]  G. Murphy,et al.  LNCaP model of human prostatic carcinoma. , 1983, Cancer research.

[53]  E. Gelmann,et al.  p53 oncogene mutations in human prostate cancer specimens. , 1994, The Journal of urology.

[54]  E. Liu,et al.  p53 gene alterations in human prostate carcinoma. , 1993, The Journal of urology.

[55]  H. Tucker,et al.  The preclinical development of bicalutamide: pharmacodynamics and mechanism of action. , 1996, Urology.

[56]  W. W. Nichols,et al.  p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. , 1993, Journal of the National Cancer Institute.

[57]  D. Bostwick Progression of prostatic intraepithelial neoplasia to early invasive adenocarcinoma. , 1996, European urology.

[58]  S. Piantadosi,et al.  Clinical evidence for and implications of the multistep development of prostate cancer. , 1990, The Journal of urology.

[59]  Austin Ge,et al.  Antibodies to ras oncogene p21 proteins lack immunohistochemical specificity for neoplastic epithelium in human prostate tissue. , 1989 .

[60]  W. Isaacs,et al.  Androgen receptor gene mutations in human prostate cancer. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[61]  J. Barrett,et al.  KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. , 1995, Science.

[62]  M. Kattan,et al.  Perineural invasion of prostate carcinoma cells is associated with reduced apoptotic index , 1996, Cancer.

[63]  J. A. van der Korput,et al.  Expression of cellular oncogenes in human prostatic carcinoma cell lines. , 1985, Biochemical and biophysical research communications.

[64]  J. Heino Biology of tumor cell invasion: Interplay of cell adhesion and matrix degradation , 1996, International journal of cancer.

[65]  Thomas J. White,et al.  PCR protocols: a guide to methods and applications. , 1990 .

[66]  V. Jackson Studies on histone organization in the nucleosome using formaldehyde as a reversible cross-linking agent , 1978, Cell.

[67]  K. Yamamoto,et al.  Signal transduction by steroid hormones: nuclear localization is differentially regulated in estrogen and glucocorticoid receptors. , 1990, Cell regulation.

[68]  W. Sakr,et al.  Fluorescence in situ hybridization analysis of 8p allelic loss and chromosome 8 instability in human prostate cancer. , 1994, Cancer research.

[69]  J. Sklar,et al.  DNA hybridization in diagnostic pathology. , 1985, Human pathology.

[70]  M. R. Cooper,et al.  Antitumor activity of suramin in hormone‐refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables , 1995, Cancer.

[71]  Andrew A. Marino,et al.  Association between cell membrane potential and breast cancer. , 1994, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[72]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[73]  W. Lee,et al.  A case of synovial sarcoma with abnormal expression of the human retinoblastoma susceptibility gene. , 1988, Human pathology.

[74]  P. Ekman,et al.  Steroid receptor profile in human prostate cancer metastases as compared with primary prostatic carcinoma , 1991, The Prostate.

[75]  T. Stamey,et al.  Activated ki‐ras oncogene in human prostatic adenocarcinoma , 1987, The Prostate.

[76]  Jorma Isola,et al.  In vivo amplification of the androgen receptor gene and progression of human prostate cancer , 1995, Nature Genetics.

[77]  W. Birchmeier,et al.  Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. , 1994, Biochimica et biophysica acta.

[78]  W. Isaacs,et al.  ras gene mutations in human prostate cancer. , 1990, Cancer research.

[79]  J. Moul,et al.  Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. , 1994, Cancer research.

[80]  J. Epstein,et al.  Nucleoli in low-grade prostate adenocarcinoma and adenosis. , 1993, Human pathology.

[81]  C. Marshall Tumor suppressor genes , 1991, Cell.

[82]  A. Schally,et al.  Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer. , 1994, Cancer research.

[83]  Chung Lee,et al.  In vivo andin vitro approaches to study metastasis in human prostatic cancer , 1993, Cancer and Metastasis Reviews.

[84]  M. Brawer,et al.  Topography of neovascularity in human prostate carcinoma , 1995, Cancer.

[85]  P. Scardino,et al.  Association of transforming growth factor-beta 1 with prostate cancer: an immunohistochemical study. , 1993, Human pathology.

[86]  M. Barbacid,et al.  ras oncogenes: their role in neoplasia , 1990, European journal of clinical investigation.

[87]  M. Kanzaki,et al.  Expression of Calcium-permeable Cation Channel CD20 Accelerates Progression through the G1 Phase in Balb/c 3T3 Cells(*) , 1995, The Journal of Biological Chemistry.

[88]  C. Collins,et al.  Prognostic value of c-erbB-2 and epidermal growth factor receptor in stage A1 (T1a) prostatic adenocarcinoma. , 1994, British journal of urology.

[89]  U. Stein,et al.  Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate: simultaneous demonstration of cell-specific epithelial markers. , 1994, Human pathology.

[90]  L. Liotta,et al.  Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. , 1995, Cancer research.

[91]  W. Sakr,et al.  Cytogenetics of primary prostatic adenocarcinoma. Clonality and chromosome instability. , 1992, Cancer genetics and cytogenetics.

[92]  William B. Isaacs,et al.  Establishment and characterization of seven dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers , 1986 .

[93]  P. Wingo,et al.  Cancer statistics, 1996 , 1996, CA: a cancer journal for clinicians.

[94]  E. Wanke,et al.  Integrin-mediated neurite outgrowth in neuroblastoma cells depends on the activation of potassium channels , 1993, The Journal of cell biology.

[95]  M. Steiner,et al.  Transforming growth factor-beta 1 overproduction in prostate cancer: effects on growth in vivo and in vitro. , 1992, Molecular endocrinology.

[96]  M. Neumaier,et al.  CD66a (BGP), an adhesion molecule of the carcinoembryonic antigen family, is expressed in epithelium, endothelium, and myeloid cells in a wide range of normal human tissues. , 1996, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[97]  H. Klocker,et al.  Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. , 1995, European urology.

[98]  M. Greenberg,et al.  L-type voltage-sensitive calcium channel activation stimulates gene expression by a serum response factor-dependent pathway. , 1994, The Journal of biological chemistry.

[99]  C. Eaton,et al.  Growth factor involvement and oncogene expression in prostatic tumours. , 1988, Journal of steroid biochemistry.

[100]  R. White,et al.  Suppression of the malignant phenotype of human prostate cancer cell line PPC-1 by introduction of normal fragments of human chromosome 10. , 1996, Cancer research.

[101]  H. Poulsen,et al.  Transforming growth factor and cancer , 1995 .

[102]  R C Smith,et al.  Effect of epidermal growth factor on prostate cancer cell line PC3 growth and invasion , 1994, The Prostate.

[103]  D. D'Amico,et al.  Sex steroids up-regulate E-cadherin expression in hormone-responsive LNCaP human prostate cancer cells. , 1995, Biochemical and biophysical research communications.

[104]  F. Collins,et al.  Mutations in the p53 gene occur in diverse human tumour types , 1989, Nature.

[105]  T. Stephenson,et al.  Absence of S‐100 protein in prostatic glands , 1988, Histopathology.

[106]  S. Dedhar,et al.  Stimulation of tyrosine phosphorylation of distinct proteins in response to antibody-mediated ligation and clustering of alpha 3 and alpha 6 integrins. , 1995, Journal of cell science.

[107]  S. Batra,et al.  Effect of calcium and calcium antagonists on 45Ca influx and cellular growth of human prostatic tumor cells , 1991, The Prostate.

[108]  J. Moul,et al.  Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma. , 1993, The Journal of urology.

[109]  T. Vogt,et al.  Comparison of DNA ploidy in prostatic intraepithelial neoplasia and invasive carcinoma of the prostate: an image cytometric study. , 1994, Human pathology.

[110]  E. Greenberg,et al.  Changes in prostate cancer incidence and treatment in USA , 1994, The Lancet.

[111]  D. Rose,et al.  Autocrine regulation of DU145 human prostate cancer cell growth by epidermal growth factor‐related polypeptides , 1991, The Prostate.

[112]  V. Reuter,et al.  Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma , 1993, Cancer.

[113]  D. Grignon,et al.  Interobserver Reproducibility in the Diagnosis of Prostatic Intraepithelial Neoplasia , 1995, The American journal of surgical pathology.

[114]  T. Tong,et al.  Cancer statistics, 1994 , 1994, CA: a cancer journal for clinicians.

[115]  Ankita Patel,et al.  Frequency and pattern of karyotypic abnormalities in human prostate cancer. , 1990, Cancer research.

[116]  D. Hixson,et al.  Structure and function of C-CAM1: effects of the cytoplasmic domain on cell aggregation. , 1995, The Biochemical journal.

[117]  H. Perlman,et al.  Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. , 1995, Cancer research.

[118]  P. diSant’Agnese,et al.  The neuroendocrine prostate: characterization and quantitation of calcitonin in the human gland. , 1989, The Journal of urology.

[119]  W. Cavenee,et al.  Molecular mechanisms of oncogenesis. , 1989, Laboratory investigation; a journal of technical methods and pathology.

[120]  J. Wrathall,et al.  Regulation of growth by a nerve growth factor-like protein which modulates paracrine interactions between a neoplastic epithelial cell line and stromal cells of the human prostate. , 1991, Cancer research.

[121]  W. Isaacs,et al.  Allelic loss of chromosomes 16q and 10q in human prostate cancer. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[122]  A. Schwab,et al.  Oscillating activity of a Ca(2+)-sensitive K+ channel. A prerequisite for migration of transformed Madin-Darby canine kidney focus cells. , 1994, The Journal of clinical investigation.

[123]  J. Moul,et al.  Detection of RAS mutations in archival testicular germ cell tumors by polymerase chain reaction and oligonucleotide hybridization , 1992, Genes, chromosomes & cancer.

[124]  N. Kyprianou,et al.  Association states of androgen receptors in nuclei of human benign hypertrophic prostate , 1986, The Prostate.

[125]  A. Partin,et al.  Early cell motility changes associated with an increase in metastatic ability in rat prostatic cancer cells transfected with the v-Harvey-ras oncogene. , 1988, Cancer research.

[126]  J. Trapman,et al.  Two different, overlapping pathways of transcription initiation are active on the TATA-less human androgen receptor promoter. The role of Sp1. , 1993, The Journal of biological chemistry.

[127]  J. Milios,et al.  Cytokeratin and vimentin intermediate filament proteins in benign and neoplastic prostatic epithelium , 1988, Histopathology.

[128]  N. Kyprianou,et al.  Activation of a Ca2+−Mg2+‐dependent endonuclease as an early event in castration‐induced prostatic cell death , 1988, The Prostate.

[129]  H. Kumagai,et al.  Transglycosylation activity of Mucor hiemalis endo-beta-N-acetyl-glucosaminidase which transfers complex oligosaccharides to the N-acetylglucosamine moieties of peptides. , 1994, Biochemical and biophysical research communications.

[130]  J. Vane,et al.  Rat endothelin is a vasodilator in the isolated perfused mesentery of the rat. , 1989, European journal of pharmacology.

[131]  M. Stearns,et al.  Autocrine factors, type IV collagenase secretion and prostatic cancer cell invasion , 1993, Cancer and Metastasis Reviews.

[132]  M. Sokolovsky,et al.  Evidence for involvement of the voltage-dependent Na+ channel gating in depolarization-induced activation of G-proteins. , 1993, The Journal of biological chemistry.

[133]  R. Matusik,et al.  Expression of the c-myc protooncogene in human prostatic carcinoma and benign prostatic hyperplasia. , 1986, Cancer research.

[134]  M. Brawer,et al.  Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity , 1994, Cancer.

[135]  E. Neher Ion channels for communication between and within cells , 1992, Neuron.

[136]  S. Woolf Screening for prostate cancer with prostate-specific antigen. An examination of the evidence. , 1995, The New England journal of medicine.

[137]  S. H. Lin,et al.  Application of a tumor suppressor (C-CAM1)-expressing recombinant adenovirus in androgen-independent human prostate cancer therapy: a preclinical study. , 1995, Cancer research.

[138]  R. Nagle,et al.  Expression of hemidesmosomal and extracellular matrix proteins by normal and malignant human prostate tissue. , 1995, The American journal of pathology.

[139]  A. Melman,et al.  Elevated plasma levels of TGF-β1 in patients with invasive prostate cancer , 1995, Nature Medicine.

[140]  D. Djakiew,et al.  Stromal-epithelial paracrine interactions in the neoplastic rat and human prostate. , 1993, Advances in experimental medicine and biology.

[141]  D. Bostwick,et al.  Frequent loss of heterozygosity at 7q31.1 in primary prostate cancer is associated with tumor aggressiveness and progression. , 1995, Cancer research.

[142]  R. Nagle,et al.  Adhesion molecules, extracellular matrix, and proteases in prostate carcinoma. , 1994, Journal of cellular biochemistry. Supplement.

[143]  O. Cussenot,et al.  A microdissection approach to detect molecular markers during progression of prostate cancer. , 1995, British Journal of Cancer.

[144]  D. Albanes,et al.  The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. , 1994, The New England journal of medicine.

[145]  T. Sekiya,et al.  Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[146]  Y. Huang,et al.  Potassium channel induction by the Ras/Raf signal transduction cascade. , 1994, The Journal of biological chemistry.

[147]  P. Kostenuik,et al.  Bone cell matrix promotes the adhesion of human prostatic carcinoma cells via the α2β1 integrin , 2004, Clinical & Experimental Metastasis.

[148]  S. H. Lin,et al.  Androgen regulation of cell adhesion molecule gene expression in rat prostate during organ degeneration. C-CAM belongs to a class of androgen-repressed genes associated with enriched stem/amplifying cell population after prolonged castration. , 1994, The Journal of biological chemistry.

[149]  R. Weinberg,et al.  Deletions of a DNA sequence in retinoblastomas and mesenchymal tumors: organization of the sequence and its encoded protein. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[150]  J D Siegal,et al.  Enhanced expression of the c‐myc protooncogene in high‐grade human prostate cancers , 1988, The Prostate.

[151]  David G. Bostwick,et al.  High grade prostatic intraepithelial neoplasia. The most likely precursor of prostate cancer , 1995 .

[152]  R. Nagle,et al.  Integrin α6 expression in human prostate carcinoma cells is associated with a migratory and invasive phenotypein vitro andin vivo , 1995, Clinical & Experimental Metastasis.

[153]  J. Massagué,et al.  Early gene responses to transforming growth factor-beta in cells lacking growth-suppressive RB function , 1991, Molecular and cellular biology.

[154]  F. McCormick,et al.  Activators and effectors of ras p21 proteins. , 1994, Current opinion in genetics & development.

[155]  J. Srigley,et al.  Basal epithelial cells of human prostate gland are not myoepithelial cells. A comparative immunohistochemical and ultrastructural study with the human salivary gland. , 1990, The American journal of pathology.

[156]  R. Evans,et al.  The steroid and thyroid hormone receptor superfamily. , 1988, Science.

[157]  P. Walsh,et al.  Subcellular distribution of androgen receptors in human normal, benign hyperplastic, and malignant prostatic tissues: characterization of nuclear salt-resistant receptors. , 1983, Cancer research.

[158]  J. Mendelsohn,et al.  Autonomous growth of androgen-independent human prostatic carcinoma cells: role of transforming growth factor alpha. , 1991, Cancer research.

[159]  J. Nelson,et al.  Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate , 1995, Nature Medicine.

[160]  G. R. Taylor,et al.  PCR: a practical approach. , 1991 .

[161]  J. Isaacs,et al.  Inhibition of tumor angiogenesis and the therapeutic ability of linomide against rat prostatic cancers , 1995, The Prostate.

[162]  J. Schalken,et al.  Decreased expression of E-cadherin in the progression of rat prostatic cancer. , 1992, Cancer research.

[163]  G. Miller,et al.  Stable expression of the nuclear vitamin D receptor in the human prostatic carcinoma cell line JCA-1: evidence that the antiproliferative effects of 1 alpha, 25-dihydroxyvitamin D3 are mediated exclusively through the genomic signaling pathway. , 1996, Endocrinology.

[164]  E. Barrack,et al.  Modulation of transforming growth factor beta 1 effects on prostate cancer cell proliferation by growth factors and extracellular matrix. , 1995, Cancer research.

[165]  A. Brothman,et al.  Characterization of 10 marker chromosomes in a prostatic cancer cell line by in situ hybridization. , 1992, Cytogenetics and cell genetics.

[166]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[167]  P. Walsh,et al.  Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. , 1993, Cancer research.

[168]  J. Trapman,et al.  Androgen receptor abnormalities , 1991, The Journal of Steroid Biochemistry and Molecular Biology.

[169]  H. Morrison,et al.  Farming and prostate cancer mortality. , 1993, American journal of epidemiology.

[170]  U. Falkmer Methodologic sources of errors in image and flow cytometric DNA assessments of the malignancy potential of prostatic carcinoma. , 1992, Human pathology.

[171]  D. Bostwick,et al.  Loss of chromosome arm 8p loci in prostate cancer: Mapping by quantitative allelic imbalance , 1994, Genes, chromosomes & cancer.

[172]  A. Belldegrun,et al.  Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[173]  J. Ramsdell,et al.  Maitotoxin, a calcium channel activator, inhibits cell cycle progression through the G1/S and G2/M transitions and prevents CDC2 kinase activation in GH4C1 cells , 1996, Journal of cellular physiology.

[174]  P. Walsh Using Prostate-specific Antigen To Diagnose Prostate Cancer: Sailing in Uncharted Waters , 1993, Annals of Internal Medicine.

[175]  W. Lee,et al.  Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. , 1990, Science.

[176]  F. S. French,et al.  Oncogene expression in prostate cancer: Dunning R3327 rat dorsal prostatic adenocarcinoma system , 1988, The Prostate.

[177]  E. Johnson,et al.  Effects of nerve growth factor on rat peritoneal mast cells. Survival promotion and immediate-early gene induction. , 1994, The Journal of biological chemistry.

[178]  J. Kim,et al.  Inhibition of prostatic tumor cell proliferation by suramin: alterations in TGF alpha-mediated autocrine growth regulation and cell cycle distribution. , 1991, The Journal of urology.

[179]  J. Ferlay,et al.  Estimates of the worldwide incidence of eighteen major cancers in 1985 , 1993, International journal of cancer.

[180]  T. P. Pretlow,et al.  Expression of E-cadherin in primary and metastatic prostate cancer. , 1996, The American journal of pathology.

[181]  J. Barrett,et al.  An amino-terminal c-myc domain required for neoplastic transformation activates transcription , 1990, Molecular and cellular biology.

[182]  E. Rimm,et al.  A prospective study of dietary fat and risk of prostate cancer. , 1993, Journal of the National Cancer Institute.

[183]  P. Green,et al.  Identification of p53 gene mutations in bladder cancers and urine samples. , 1991, Science.

[184]  H. Bonkhoff,et al.  Widespread distribution of nuclear androgen receptors in the basal cell layer of the normal and hyperplastic human prostate , 2005, Virchows Archiv A.

[185]  A. Wells,et al.  In vitro invasiveness of DU-145 human prostate carcinoma cells is modulated by EGF receptor-mediated signals , 1995, Clinical & Experimental Metastasis.

[186]  A. Levine The tumor suppressor genes. , 1993, Annual review of biochemistry.

[187]  C. Wilson,et al.  Androgen Receptor Gene Expression in Human Prostate Carcinoma Cell Lines1 , 1990 .

[188]  N. Block,et al.  Secretion of matrix metalloproteinases and their inhibitors (tissue inhibitor of metalloproteinases) by human prostate in explant cultures: reduced tissue inhibitor of metalloproteinase secretion by malignant tissues. , 1993, Cancer research.

[189]  J. Minna,et al.  Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. , 1988, Science.

[190]  P. Boyle,et al.  Incidence of prostate cancer will double by the year 2030: the argument for. , 1996, European urology.

[191]  B. Groner,et al.  Overexpression of the c‐erbB‐2 protein in human breast tumor cell lines , 1989, Journal of cellular biochemistry.

[192]  J. Herman,et al.  E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. , 1995, Cancer research.

[193]  J. Dodd,et al.  Epidermal growth factor receptor mRNA levels in human prostatic tumors and cell lines. , 1990, The Journal of urology.

[194]  J. Isaacs,et al.  Human prostatic cancer cells are sensitive to programmed (apoptotic) death induced by the antiangiogenic agent linomide. , 1995, Cancer research.

[195]  S. Dedhar,et al.  The receptor for the basement membrane glycoprotein entactin is the integrin alpha 3/beta 1. , 1992, The Journal of biological chemistry.

[196]  N. Block,et al.  Association of elevated levels of hyaluronidase, a matrix-degrading enzyme, with prostate cancer progression. , 1996, Cancer research.

[197]  F. S. French,et al.  Expression of ras proto‐oncogenes in the dunning R3327 rat prostatic adenocarcinoma system , 1988, The Prostate.

[198]  R. deVere White,et al.  Flow cytometry as a predictive modality in prostate cancer. , 1992, Human pathology.

[199]  L. Jin,et al.  Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups. , 1992, Genomics.

[200]  O. Chinot,et al.  Divergent effect of TGFβ1 on growth and proteolytic modulation of human prostatic‐cancer cell lines , 1996 .

[201]  W. J. Brammar,et al.  The retinoblastoma gene is frequently altered leading to loss of expression in primary breast tumours. , 1989, Oncogene.

[202]  J. Schalken,et al.  Decreased expression of the intercellular adhesion molecule E-cadherin in prostate cancer: Biological significance and clinical implications , 1993, Cancer and Metastasis Reviews.

[203]  Y. Furuya,et al.  The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin. , 1994, Cancer research.

[204]  D. Yin,et al.  Combination therapy with cisplatin and nifedipine induces apoptosis in cisplatin-sensitive and cisplatin-resistant human glioblastoma cells. , 1995, British Journal of Cancer.

[205]  L. Chung,et al.  Stromal-epithelial interactions--I. Induction of prostatic phenotype in urothelium of testicular feminized (Tfm/y) mice. , 1981, Journal of steroid biochemistry.

[206]  G. Collina,et al.  Sclerosing adenosis of the prostate. Report of three cases with electronmicroscopy and immunohistochemical study , 1992, Histopathology.

[207]  W. Birchmeier,et al.  E-cadherin and APC compete for the interaction with beta-catenin and the cytoskeleton , 1994, The Journal of cell biology.

[208]  P. Troncoso,et al.  Trisomy 7: A potential cytogenetic marker of human prostate cancer progression , 1994, Genes, chromosomes & cancer.

[209]  H. Wiley,et al.  Androgens regulate proliferation of human prostate cancer cells in culture by increasing transforming growth factor-alpha (TGF-alpha) and epidermal growth factor (EGF)/TGF-alpha receptor. , 1993, The Journal of clinical endocrinology and metabolism.

[210]  N. Sato,et al.  Androgen receptor gene mutations in human prostate cancer , 1993, The Journal of Steroid Biochemistry and Molecular Biology.

[211]  K. Pienta,et al.  A comparative study on expression of prostatic inhibin peptide, prostate acid phosphatase and prostate specific antigen in androgen independent human and rat prostate carcinoma cell lines. , 1993, Cancer letters.

[212]  E. Bergstralh,et al.  Aneuploidy and aneusomy of chromosome 7 detected by fluorescence in situ hybridization are markers of poor prognosis in prostate cancer. , 1994, Cancer research.

[213]  M. Stearns,et al.  IL-10 blocks collagen IV invasion by "invasion stimulating factor" activated PC-3 ML cells: upregulation of TIMP-1 expression. , 1995, Oncology research.

[214]  R. Nagle,et al.  The α6β1 and α6β4 integrins in human prostate cancer progression , 1995, Cancer and Metastasis Reviews.

[215]  W. Sakr,et al.  DNA quantitation of intraepithelial neoplasia and invasive carcinoma of the prostate , 1993, The Prostate.

[216]  H. Adami,et al.  Perinatal characteristics in relation to incidence of and mortality from prostate cancer , 1996, BMJ.

[217]  D. Pa,et al.  Human prostatic endocrine-paracrine (APUD) cells. Distributional analysis with a comparison of serotonin and neuron-specific enolase immunoreactivity and silver stains. , 1985 .

[218]  M. Brawer,et al.  Expression of metalloproteinase genes in human prostate cancer , 2005, Journal of Cancer Research and Clinical Oncology.

[219]  L. Eliasson,et al.  Co‐localization of L‐type Ca2+ channels and insulin‐containing secretory granules and its significance for the initiation of exocytosis in mouse pancreatic B‐cells. , 1995, The EMBO journal.

[220]  J. McNeal,et al.  Differential cytokeratin expression in normal, hyperplastic and malignant epithelial cells from human prostate. , 1990, The Journal of urology.

[221]  R. Weinberg,et al.  Tumor suppressor genes. , 1991, Science.

[222]  S. Friend,et al.  Cancer risks from germline p53 mutations. , 1992, The Journal of clinical investigation.

[223]  M. Watsky Loss of keratocyte ion channels during wound healing in the rabbit cornea. , 1995, Investigative ophthalmology & visual science.

[224]  B. Hille Ionic channels of excitable membranes , 2001 .

[225]  W. Catterall,et al.  Calcium-dependent interaction of N-type calcium channels with the synaptic core complex , 1996, Nature.

[226]  B. Oostra,et al.  Trinucleotide (GGN) repeat polymorphism in the human androgen receptor (AR) gene. , 1993, Human molecular genetics.

[227]  G. Folprecht,et al.  Polarized ion transport during migration of transformed Madin-Darby canine kidney cells , 1995, Pflügers Archiv.

[228]  J. Ross,et al.  E-cadherin expression in prostatic carcinoma biopsies: correlation with tumor grade, DNA content, pathologic stage, and clinical outcome. , 1994, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[229]  O. Rokhlin,et al.  Expression of cellular adhesion molecules on human prostate tumor cell lines , 1995, The Prostate.

[230]  U. Stein,et al.  Androgen receptor status in endocrine-paracrine cell types of the normal, hyperplastic, and neoplastic human prostate , 2005, Virchows Archiv A.

[231]  K. Fischbeck,et al.  Microsatellite mutation (CAG24-->18) in the androgen receptor gene in human prostate cancer. , 1994, Biochemical and biophysical research communications.

[232]  T. Tsuruo,et al.  Enhancement of voltage-gated Na+ channel current associated with multidrug resistance in human leukemia cells. , 1987, Cancer research.

[233]  J. Mohler Cellular motility and prostatic carcinoma metastases , 1993, Cancer and Metastasis Reviews.

[234]  F. Schröder,et al.  Detection of prostate cancer. , 1995, BMJ.

[235]  J. Varley,et al.  Structural rearrangement of the retinoblastoma gene in human breast carcinoma. , 1988, Science.

[236]  E. Gelmann,et al.  v-rasH expression confers hormone-independent in vitro growth to LNCaP prostate carcinoma cells. , 1991, Molecular endocrinology.

[237]  V. P. Collins,et al.  Allelotyping of human prostatic adenocarcinoma. , 1991, Genomics.

[238]  J. Brooks,et al.  Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinomas , 1995, The Prostate.

[239]  R. Ueda,et al.  The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern. , 1991, Oncogene.

[240]  C R King,et al.  Amplification of a novel v-erbB-related gene in a human mammary carcinoma. , 1985, Science.

[241]  A. Zlotta,et al.  Prostatic intraepithelial neoplasia: influence of clinical and pathological data on the detection of prostate cancer. , 1996, The Journal of urology.

[242]  J. Underwood Diagnostic Molecular Pathology. A Practical Approach , 1993 .

[243]  G. Haas,et al.  The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. , 1993, The Journal of urology.

[244]  F. Schröder,et al.  Neuroendocrine cells in the normal, hyperplastic and neoplastic prostate , 2004, Urological Research.

[245]  S. H. Lin,et al.  Tumor suppressive role of an androgen-regulated epithelial cell adhesion molecule (C-CAM) in prostate carcinoma cell revealed by sense and antisense approaches. , 1995, Cancer research.

[246]  M. Hollstein,et al.  Clinical implications of the p53 tumor-suppressor gene. , 1993, The New England journal of medicine.

[247]  F. Habib,et al.  Levels of circulating intercellular adhesion molecule-1 in patients with metastatic cancer of the prostate and benign prostatic hyperplasia. , 1995, European journal of cancer.

[248]  M. Stearns,et al.  Immunoassays of the metalloproteinase (MMP-2) and tissue inhibitor of metalloproteinase (TIMP 1 and 2) levels in noninvasive and metastatic PC-3 clones: effects of taxol. , 1994, Oncology research.

[249]  W. Allsbrook,et al.  Histochemistry of the prostate. , 1992, Human pathology.

[250]  B A Miller,et al.  The role of increasing detection in the rising incidence of prostate cancer. , 1995, JAMA.

[251]  R. Hall Screening and early detection of prostate cancer will decrease morbidity and mortality from prostate cancer: the argument against. , 1996, European urology.

[252]  J. Isaacs,et al.  Expression of a transfected v-Harvey-ras oncogene in a Dunning rat prostate adenocarcinoma and the development of high metastatic ability. , 1988, The Journal of urology.

[253]  M. Litwin,et al.  Identification of an endogenous inhibitor of prostatic carcinoma cell growth , 1995, Nature Medicine.

[254]  C. Cordon-Cardo,et al.  Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. , 1994, The Journal of urology.

[255]  W. Isaacs,et al.  Chromosome 5 suppresses tumorigenicity of PC3 prostate cancer cells: correlation with re-expression of alpha-catenin and restoration of E-cadherin function. , 1995, Cancer research.

[256]  J. Isaacs,et al.  Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers. , 1995, Cancer research.

[257]  T. Visakorpi,et al.  Expression of epidermal growth factor receptor and ERBB2 (HER-2/Neu) oncoprotein in prostatic carcinomas. , 1992, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[258]  R. Matusik,et al.  Expression of the c-myc proto-oncogene in prostatic tissue. , 1987, Progress in clinical and biological research.

[259]  P C Prorok,et al.  Prostate Cancer Screening: What We Know and What We Need To Know , 1993, Annals of Internal Medicine.

[260]  A. Jenei,et al.  Ion-channel activities regulate transmembrane signaling in thymocyte apoptosis and T-cell activation. , 1995, Immunology letters.

[261]  I. Fidler,et al.  Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells , 1995, The Journal of experimental medicine.

[262]  A. Gown,et al.  Monoclonal antibodies to human intermediate filament proteins. II. Distribution of filament proteins in normal human tissues. , 1984, The American journal of pathology.

[263]  J. Crocker Molecular biology in histopathology , 1994 .

[264]  R. Nagle,et al.  Differential expression of extracellular matrix molecules and the alpha 6-integrins in the normal and neoplastic prostate. , 1994, The American journal of pathology.

[265]  T. Sekiya,et al.  Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. , 1989, Genomics.

[266]  E. Corder,et al.  Vitamin D and prostate cancer: a prediagnostic study with stored sera. , 1993, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[267]  K. Mullis,et al.  Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction. , 1987, Methods in enzymology.

[268]  C. Foster,et al.  Differential expression of voltage‐activated Na+ currents in two prostatic tumour cell lines: contribution to invasiveness in vitro , 1995, FEBS letters.

[269]  K. Fan,et al.  Heterogeneous subpopulations of human prostatic adenocarcinoma cells: potential usefulness of P21 protein as a predictor for bone metastasis. , 1988, The Journal of urology.

[270]  R. Nagle,et al.  Matrilysin expression in human prostate carcinoma , 1996, Molecular carcinogenesis.

[271]  C. Bird,et al.  Recombinant DNA technology and its diagnostic applications , 1992, Histopathology.

[272]  J. Schalken,et al.  Oncogene expression in prostate cancer , 1991, World Journal of Urology.

[273]  Y. Hirata,et al.  Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. , 1993, The Journal of clinical investigation.

[274]  N. Chamberlain,et al.  The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. , 1994, Nucleic acids research.

[275]  Thomas,et al.  Consistent expression of an epithelial cell adhesion molecule (C-CAM) during human prostate development and loss of expression in prostate cancer: implication as a tumor suppressor. , 1995, Cancer research.

[276]  J. Mohler,et al.  Prediction of metastatic potential by cancer cell motility in the Dunning R-3327 prostatic adenocarcinoma in vivo model. , 1992, The Journal of urology.

[277]  G. Coetzee,et al.  The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. , 1995, Cancer research.

[278]  E. Gelmann,et al.  Differential effects of transforming growth factor β on human prostate cancer cells in vitro , 1989, Molecular and Cellular Endocrinology.

[279]  R. Kiss,et al.  In vitro characterization of prolactin‐induced effects on proliferation in the neoplastic LNCaP, DU145, and PC3 models of the human prostate , 1996, Cancer.

[280]  A. Passaniti,et al.  Immortalization of human adult prostatic adenocarcinoma cells by human papilloma virus HPV16 and -18 DNA. , 1996, Cancer letters.

[281]  J. Epstein,et al.  Use of Keratin 903 as an Adjunct in the Diagnosis of Prostate Carcinoma , 1989, The American journal of surgical pathology.

[282]  F. Guillé,et al.  Pretherapeutic erythrocyte polyamine spermine levels discriminate high risk relapsing patients with M1 prostate carcinoma , 1996, Cancer.

[283]  J. Isaacs,et al.  Role of calcium in the programmed death of rat prostatic glandular cells , 1990, The Prostate.

[284]  G. Wilding,et al.  Effects of Interferon βser and Transforming Growth Factor β on Prostatic Cell Lines , 1991 .

[285]  T. Visakorpi,et al.  Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. , 1992, Journal of the National Cancer Institute.

[286]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[287]  J. Epstein,et al.  Utilization of high molecular weight cytokeratin on prostate needle biopsies in an independent laboratory. , 1995, Urology.

[288]  W. Isaacs,et al.  Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. , 1994, Cancer research.

[289]  N. Breslow,et al.  Latent carcinoma of prostate at autopsy in seven areas. Collaborative study organized by the International Agency for Research on Cancer, Lyons, France , 1977, International journal of cancer.

[290]  G. Miller,et al.  Expression of c‐erb B‐2/neu proto‐oncogene in human prostatic cancer tissues and cell lines , 1992, Molecular carcinogenesis.

[291]  A. Schally,et al.  Inhibitory effects of analogs of luteinizing hormone‐releasing hormone on the growth of the androgen‐independent dunning R‐3327‐AT‐1 rat prostate cancer , 1994, International journal of cancer.

[292]  S. Soker,et al.  Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. , 1995, Cancer research.

[293]  S. Rabbani,et al.  Induction of urinary plasminogen activator by retinoic acid results in increased invasiveness of human prostate cancer cells PC‐3 , 1995, The Prostate.

[294]  G. Cunha Epithelial-stromal interactions in development of the urogenital tract. , 1976, International review of cytology.

[295]  H. Nordgren,et al.  In situ expression of mRNA for proto-oncogenes in benign prostatic hyperplasia and in prostatic carcinoma. , 1991, Scandinavian journal of urology and nephrology.

[296]  F. Bosman,et al.  Loss of heterozygosity of chromosome 8 microsatellite loci implicates a candidate tumor suppressor gene between the loci D8S87 and D8S133 in human prostate cancer. , 1994, Cancer research.

[297]  J. Folkman,et al.  A strategy to discover circulating angiogenesis inhibitors generated by human tumors. , 1995, Cancer research.

[298]  W. Isaacs,et al.  Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. , 1992, Cancer research.

[299]  A. Passaniti,et al.  Antiangiogenic effects of the quinoline-3-carboxamide linomide. , 1993, Cancer research.

[300]  F. Bosman,et al.  Frequency and characterization of p53 mutations in primary and metastatic human prostate cancer , 1994, International journal of cancer.

[301]  H. Naiki,et al.  Presence of ras oncogene mutations and human papillomavirus DNA in human prostate carcinomas. , 1992, Cancer research.

[302]  T. Stamey,et al.  Clonal growth of human prostatic epithelial cells is stimulated by fibroblasts , 1989, The Prostate.

[303]  C. Blat,et al.  IGF-I and IGF-binding proteins: stimulatory and inhibitory factors secreted by human prostatic adenocarcinoma cells. , 1991, Growth factors.

[304]  D. Djakiew,et al.  Chemotaxis and chemokinesis of human prostate tumor cell lines in response to human prostate stromal cell secretory proteins containing a nerve growth factor-like protein. , 1993, Cancer research.

[305]  J. McNeal,et al.  Normal histology of the prostate. , 1988, The American journal of surgical pathology.

[306]  W. Catterall,et al.  Structure and function of the β2 subunit of brain sodium channels, a transmembrane glycoprotein with a CAM motif , 1995, Cell.

[307]  C. Eaton,et al.  Growth Factor Receptors and Oncogene Expression in Prostate Cells , 1988, American journal of clinical oncology.

[308]  L. Donehower,et al.  The tumore suppressor p53 , 1993 .

[309]  M. Brawer,et al.  Serum basic fibroblast growth factor in men with and without prostate carcinoma , 1995, Cancer.

[310]  M. Gleave,et al.  Prostate and bone fibroblasts induce human prostate cancer growth in vivo: implications for bidirectional tumor-stromal cell interaction in prostate carcinoma growth and metastasis. , 1992, The Journal of urology.

[311]  C. Polychronakos,et al.  Mitogenic effects of insulin and insulin‐like growth factors on PA‐III rat prostate adenocarcinoma cells: Characterization of the receptors involved , 1991, The Prostate.

[312]  L. Strong,et al.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.

[313]  J. Bishop Molecular themes in oncogenesis , 1991, Cell.

[314]  G. Bubley,et al.  Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. , 1995, The New England journal of medicine.

[315]  David J. Grignon,et al.  The Prostatic Capsule: Does It Exist? Its Importance in the Staging and Treatment of Prostatic Carcinoma , 1989, The American journal of surgical pathology.

[316]  T M Grogan,et al.  Expression of the metalloproteinase matrilysin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice. , 1993, Cancer research.

[317]  J. Ward,et al.  K‐ras activation and ras p21 expression in latent prostatic carcinoma in Japanese men , 1992, Cancer.

[318]  P. Troncoso,et al.  Significance of tumor angiogenesis in clinically localized prostate carcinoma treated with external beam radiotherapy. , 1994, Urology.

[319]  J. Yokota,et al.  Altered expression of the retinoblastoma (RB) gene in small-cell carcinoma of the lung. , 1988, Oncogene.

[320]  J. Estève,et al.  Cancer in the European Community and its member states. , 1990, European journal of cancer.

[321]  R. Nagle,et al.  Characterization of integrin subunits, cellular adhesion and tumorgenicity of four human prostate cell lines , 1993, Journal of Cancer Research and Clinical Oncology.

[322]  Michael J. Wilson,et al.  Heterogeneity in plasminogen activator (PA) levels in human prostate cancer cell lines: Increased PA activity correlates with biologically aggressive behavior , 1991, The Prostate.

[323]  H. Dvorak,et al.  Vascular permeability factor (vascular endothelial growth factor) is strongly expressed in the normal male genital tract and is present in substantial quantities in semen. , 1995, The Journal of urology.

[324]  P. Sluss,et al.  Insulin‐like growth factor I: Action and receptor characterization in human prostate cancer cell lines , 1993, The Prostate.

[325]  M. Gleave,et al.  Reciprocal mesenchymal-epithelial interaction affecting prostate tumour growth and hormonal responsiveness. , 1991, Cancer surveys.

[326]  D. Neal,et al.  p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate. , 1992, The Journal of urology.

[327]  P. Boyle,et al.  Screening for prostate cancer--necessity or nonsense? , 1993, European journal of cancer.

[328]  P. di Sant'Agnese,et al.  Neuroendocrine cells in the human prostate gland. , 1993, Journal of andrology.

[329]  W. Fair,et al.  Expression of the prostate-specific membrane antigen. , 1994, Cancer research.

[330]  N. Block,et al.  Detection of prostatic‐inhibin‐like peptide in the cytoplasm of LNCaP cells, a human prostatic adenocarcinoma cell line , 1994, The Prostate.

[331]  J. Brooks,et al.  Genetic alterations in prostate cancer. , 1994, Cold Spring Harbor symposia on quantitative biology.

[332]  J. L. Bos,et al.  ras oncogenes in human cancer: a review. , 1989, Cancer research.

[333]  T. Lüscher,et al.  Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. , 1990, The Journal of clinical investigation.

[334]  M. Masai,et al.  Histochemical examination of expression of ras p21 protein and R 1881-binding protein in human prostatic cancers. , 1990, European journal of cancer.

[335]  M. Viola,et al.  Expression of ras oncogene p21 in prostate cancer. , 1986, The New England journal of medicine.

[336]  Schr,et al.  Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. , 1994, The American journal of pathology.

[337]  A. Partin,et al.  Prediction of metastatic potential in an animal model of prostate cancer: flow cytometric quantification of cell surface charge. , 1989, The Journal of urology.

[338]  H. Lepor,et al.  Localization of endothelin receptors in the human prostate. , 1994, The Journal of urology.

[339]  S. Hilsenbeck,et al.  p53 is mutated in a subset of advanced-stage prostate cancers. , 1993, Cancer research.

[340]  I. Nishimoto,et al.  Activation of a calcium-permeable cation channel by insulin-like growth factor II in BALB/c 3T3 cells. , 1988, The American journal of physiology.

[341]  M. Benson,et al.  Calcium channel antagonists delay regression of androgen‐dependent tissues and suppress gene activity associated with cell death , 1988, The Prostate.

[342]  D. Djakiew,et al.  Distribution of nerve growth factor-like protein and nerve growth factor receptor in human benign prostatic hyperplasia and prostatic adenocarcinoma. , 1992, The Journal of urology.

[343]  T. H. van der Kwast,et al.  Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. , 1991, Molecular endocrinology.

[344]  B. Zetter,et al.  Selective stimulation of prostatic carcinoma cell proliferation by transferrin. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[345]  T. Tsujii,et al.  [The clinical usefulness of urinary basic fetoprotein (BFP) in patients with urological malignancies]. , 1990, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

[346]  C. Tso,et al.  Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer. , 1995, Human gene therapy.

[347]  K. Yamamoto,et al.  Crystallographic analysis of the interaction of the glucocorticoid receptor with DNA , 2003, Nature.

[348]  N. Bruchovsky,et al.  DNA content in prostatic adenocarcinoma. A flow cytometry study of the predictive value of aneuploidy for tumor volume, percentage gleason grade 4 and 5, and lymph node metastases , 1990, Cancer.

[349]  M. Goligorsky,et al.  Termination of endothelin signaling: Role of nitric oxide , 1994, Journal of cellular physiology.

[350]  M. Wigler,et al.  Cloning the differences between two complex genomes , 1993, Science.

[351]  D. Rose,et al.  Secretion of epidermal growth factor and related polypeptides by the DU 145 human prostate cancer cell line , 1989, The Prostate.

[352]  D. Bostwick,et al.  The association of benign prostatic hyperplasia and cancer of the prostate , 1992, Cancer.

[353]  R. deVere White,et al.  Activated ras alleles in human carcinoma of the prostate are rare. , 1991, Cancer research.

[354]  R. Hoover,et al.  Farming and prostate cancer among African-Americans in the southeastern United States. , 1994, Journal of the National Cancer Institute.

[355]  R. Leake,et al.  Transforming growth factor-α expression in benign and malignant human prostatic disease , 1992 .

[356]  K. Ching,et al.  Expression of mRNA for epidermal growth factor, transforming growth factor-alpha and their receptor in human prostate tissue and cell lines , 1993, Molecular and Cellular Biochemistry.

[357]  Chung Lee,et al.  Genetic change in transforming growth factor β (TGF-β) receptor type I gene correlates with insensitivity to TGF-β1 in human prostate cancer cells , 1996 .

[358]  E. Dmitrovsky,et al.  Isochromosome of Chromosome 12: Clinically Useful Marker for Male Germ Cell Tumors , 1989 .

[359]  P. Smith,et al.  Intranuclear androgen receptor deployment and protooncogene expression in human diseased prostate. , 1987, Urologia internationalis.

[360]  N. Weidner,et al.  Concordance of DNA content between prostatic intraepithelial neoplasia and concomitant invasive carcinoma. Evidence that prostatic intraepithelial neoplasia is a precursor of invasive prostatic carcinoma. , 1993, Archives of pathology & laboratory medicine.

[361]  D. S. Coffey,et al.  Cell surface charge in predicting metastatic potential of aspirated cells from the Dunning rat prostatic adenocarcinoma model. , 1988, The Journal of urology.

[362]  D. Grignon,et al.  Usefulness of immunoperoxidase staining with high-molecular-weight cytokeratin in the differential diagnosis of small-acinar lesions of the prostate gland , 2005, Virchows Archiv A.

[363]  D. Peehl,et al.  The IGF axis in the prostate. , 1994, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[364]  S. Maygarden,et al.  Immunohistochemical detection of c-erbB-2 protein in human benign and neoplastic prostate. , 1991, Human pathology.

[365]  W. Whitmore Natural history of low-stage prostatic cancer and the impact of early detection. , 1990, The Urologic clinics of North America.

[366]  R. Nagle,et al.  Cytokeratin characterization of human prostatic carcinoma and its derived cell lines. , 1987, Cancer research.